Learn More
Typical use patterns of methamphetamine (MA) users were examined using self-report measures from 120 MA and 63 cocaine users. Twenty (14 MA and 6 cocaine) of the participants also took part in structured interviews designed to provide more specific descriptions of their drug use. The typical MA user uses more than 20 days a month. Use is evenly spaced(More)
Forty currently using methamphetamine (MA) abusers, 40 currently using cocaine (COC) abusers, and 80 comparison participants who did not use psychostimulants received a cognitive battery and questionnaires covering medical history and stimulant use patterns. Forty comparison participants were matched to the 40 MA users on age, education, ethnicity, and(More)
Drug courts are popular for dealing with drug-abusing offenders. However, relatively little is known about participant characteristics that reliably predict either success or failure in these treatment settings. In this article, we report on 99 individuals who were enrolled in a drug court program (approximately one-half of whom successfully completed the(More)
Understanding the association between attention deficit hyperactivity disorder (ADHD) and substance abuse, specifically methamphetamine (MA) abuse, is challenging, partly because little is known about the specific constellation of cognitive impairments produced by MA. The present investigation serves to address this relationship by comparing the cognitive(More)
The central corneal thickness, peripheral corneal thickness, central anterior chamber depth, and peripheral anterior chamber depth were measured from 110 phakic eyes using attachments 1 and 2 to the slitlamp (Haag-Streit). The Shaffer grading system was used for the width of the anterior chamber angle. The results showed that both the average central(More)
At issue on review is a citation issued by the Occupational Safety and Health Administration to the United States Postal Service regarding two OSHA recordkeeping regulations, 29 C.F.R. § 1904.29(b)(2) and (b)(3), alleging a failure to record a work-related illness on the forms required by 29 C.F.R. Part 1904. We conclude that the Secretary has failed to(More)
2027 Background: To evaluate the safety/tolerability, maximum tolerated dose (MTD), and anti-tumor effect of nanoparticle paclitaxel (ABI-007). This novel Cremophor-free formulation was administered intravenously during weekly monotherapy to patients with advanced non-hematologic malignancies. This single center, Phase I, open-label study also evaluated the(More)